Two immunotherapy drugs plus chemo before surgery for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with 2 or 4 cycles of chemotherapy before surgery can help shrink tumors and improve outcomes for people with early-stage (stage II-IIIB) non-small cell lung cancer. The goal is to make surgery more effective and possibly reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) that is stage II or III (but only T4 based on size, not if it has spread to nearby structures).
- A team of doctors, including a chest surgeon, must agree that your tumor can be completely removed by surgery.
- You must not have had any prior treatment for this cancer (no previous chemotherapy, radiation, or immunotherapy).
- You must be willing to provide a tumor sample for biomarker testing (like PD-L1).
- You must be in good overall health, able to carry out daily activities (ECOG score 0 or 1).
- You must not have a confirmed EGFR or ALK gene mutation, and you must not have had immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests a combination of two immunotherapy drugs plus chemotherapy to shrink lung tumors so they can be removed with surgery. The goal is to give patients with stage III unresectable non-small cell lung cancer a chance at surgery and a better outcome.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.